ActRIIA Enzyme Activity Inhibitor Screening Kit

STX-001, the leading program of Supercede, is a novel oral small-molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibition of the ACTRII signaling pathway has been shown to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving significant fat reduction while maintaining or increasing lean body mass is a key unmet need. Whether used as monotherapy or in combination with glucagon-like peptide-1 (GLP-1)-based therapies, ACTRII inhibition is the only clinically proven mechanism capable of achieving this beneficial change in overall body composition. Based on this, we have developed ActRIIA and ActRIIB enzymatic activity inhibitor screening kits for research and development purposes.

This kit contains the ActRIIA protein independently expressed by us and the independently designed suitable substrate. When combined with an ADP kinase detection kit, it can be used to test the inhibitory effect of compounds on ActRIIA enzymatic activity.